Clinical Trial

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Study acronym: Eluminate-2
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).
Trial Details
NCT Number NCT07662213
Lead Sponsor AstraZeneca
Conditions Type 2 Diabetes Mellitus
Enrollment 1,200 participants
Start Date 2026-07-06
Primary Completion 2028-05-23 (estimated)
Study Completion 2028-05-23 (estimated)
Updated on ClinicalTrials.gov 2026-06-23